Natco Pharma net falls 39% on lower sales

February 11, 2021 11:17 pm | Updated 11:21 pm IST - HYDERABAD

Natco Pharma reported a more than 39% decline in consolidated net profit to ₹63.40 crore for the quarter ended December, in the face of lower sales and realisation from key products.

Revenue declined almost 25% to ₹386 crore.

The decline in revenue and profits was due to lower sales in domestic oncology and weak realisation of profits from anti-viral oseltamivir (generic of Tamiflu) in the U.S., the company said on Thursday.

The firm declared a third interim dividend of ₹1 per equity share.

In terms of contribution to revenue, share of formulations exports, including profit share and foreign subsidiaries, was the highest at ₹162.1 crore, followed by APIs at ₹97.8 crore and formulations for the domestic market at ₹95.3 crore. Other income of ₹24.9 crore and other operating income of ₹5.9 crore made up the rest of the revenue.

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.